For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Gov't Has Not Yet Considered Postponing Medical, Nursing Fee Revision in 2012: Senior Vice Minister Ohtsuka
May 16, 2011
- Pfizer Allows Special Leave for Volunteers in Disaster Area
May 16, 2011
- Korosho to Create Council on Regulatory Strategies
May 16, 2011
- Discussion Starts to Revise Ethical GL for Genome Analysis
May 16, 2011
- Supreme Court Favors Patent Extension for Takeda's DDS Formulations
May 16, 2011
- Korosho Draws Up Draft Guidance for Risk Management Plans
May 16, 2011
- Kaketsuken, GSK Start PI Trial of New Cell Culture-based Flu Vaccine
May 16, 2011
- Sawai, Takeda Take Actos Patent Dispute to IP High Court
May 16, 2011
- Long-Acting ESA Mircera Approved: Chugai
May 16, 2011
- Korosho Invites Medical Societies to Present Views on 10 Switch OTC Drug Candidates
May 16, 2011
- DSP Licenses Novel Topical Analgesic to Maruho
May 16, 2011
- Glubes Approved for Type 2 Diabetes: Kissei
May 16, 2011
- Sato Pharm. Launches Switch OTC Version of Clotrimazole for Vaginal Candidiasis
May 16, 2011
- Takeda Announces Equity Investment in Fate Therapeutics of US
May 16, 2011
- Once-Daily Mirapex Approved for Parkinson's Disease: NBI
May 16, 2011
- Daiichi Sankyo to Launch AD Treatment MEMARY in June
May 16, 2011
- Pancreatic Digestive Enzyme LipaCreon Approved: Abbott Japan, Eisai
May 16, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…